VivoSeq
Other

Acanthosis Nigricans

5

Pipeline Programs

0

Active Trials

5

Companies Involved

Acanthosis Nigricans is an early-stage landscape with 5 programs across 5 companies. The most active players are Pfizer, Eastern Cooperative Oncology Group, Aucta Pharmaceuticals, Inc. 2 therapies are approved.

Pipeline Metrics

Competitive Density

27/100

Pipeline Velocity

0/100

Mech. Concentration

25/100

Completion Rate

100/100

Attrition Rate

0/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

Trial Status

7

clinical trials

Completed6 · 86%
Unknown status1 · 14%

Trial Activity

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)